tirzepatide kidney GLP therapies have established themselves as kidney-protective in type 2 diabetes and high risk of disease. This new post-hoc analysis of SURPASS-CVOT's kidney outcomes shows greater kidney protection with (#mounjaro) Kidney Outcomes in SURPASS: Exploring

First-month weight loss depends on starting dose, baseline metabolism, genetics, diet quality, and exercise

It has served as a fundamental treatment for diabetes management for over a decade, communicating satiety, slowing down digestion, and increasing insulin sensitivity

Mechanism of action: Both drugs fall into the class of medications known as GLP-1 receptor agonists that enhance insulin secretion, suppress glucagon release, and slow gastric emptying to help control blood sugar levels

5 How Wegovy works after sleeve surgery Wegovy is a GLP-1 receptor agonist

Inzucchi, S

TRPV1, Transient Receptor Potential Vanilloid 1